Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Five Prime Therapeutics (NASDAQ: FPRX ) , a clinical-stage biopharmaceutical company focused on developing protein therapeutics to fight cancer and other inflammatory diseases, jumped as much as 22% after announcing a collaborative deal with Bristol-Myers Squibb (NYSE: BMY ) before the opening bell.
So what: Under the terms of the deal, Bristol-Myers Squibb gets access to Five Prime Therapeutics' exclusive immuno-oncology platform and will decipher which therapies have the best chance of success based on two undisclosed immune checkpoint pathways. Bristol-Myers has the option of developing these cancer-fighting drugs as a single-agent therapies or can use them in combination with existing products in its own pipeline. Bristol-Myers will retain full worldwide rights to these therapies if approved.
For Five Prime, the company will receive a $20 million upfront payment from Bristol-Myers, is eligible to receive $9.5 million in researching funding over the course of its collaboration, and is getting a $21 million common equity investment from Bristol-Myers (representing a purchase of 4.9% of Five Prime's outstanding shares) at a 30% premium to Friday's closing price. In addition, it will also be eligible to receive milestone and development payments totaling as much as $300 million and tiered single-digit to double-digit royalties on any approved therapies.
Now what: Once again we see how incredibly hot cancer immunotherapies have become. A number of cancer-focused companies are realizing that it's easier to retrain the body's immune system to recognize cancer and attack it than to attempt to formulate a therapy designed to seek out cancer. It remains to be seen, of course, if this partnership will merit success, but Five Prime shareholders have to be pleased to have snagged an elephant in Bristol-Myers Squibb, which could go a long way to validating its proprietary drug discovery platform. From the standpoint of Bristol-Myers, it allows the company to potentially expand its immunotherapeutic research for a mere $50.5 million in costs, so it seems well worth the risk.
Five Prime shares may be soaring today, but it could have a difficult time keeping pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.